Stock listing
ANVS Stock Price, News, Filings & Events — Annovis Bio, Inc.
Selected listing: ANVS · NYSE · USD · US
This page tracks Annovis Bio, Inc.'s ANVS:NYSE listing on NYSE in USD for US, including stock price context, company news, filings, investor events, AI research briefs, and market updates for investors following ANVS:NYSE. ANVS:NYSE is the stock-level entry point for investors researching Annovis Bio, Inc., while company-level investor report content can remain shared across the same issuer's public listings. 6ix connects this selected listing to available company updates, filings, investor events, replay content, and AI research briefs so stock search leads to the relevant company context without making another exchange listing primary. Annovis Bio, Inc. (ticker: ANVS) is a public company based in America, with a market capitalization of approximately $70.6 million. The company focuses on developing therapies for neurodegenerative diseases. Annovis Bio aims to address significant unmet medical needs through its innovative research and development efforts.
- Ticker
- ANVS:NYSE
- Asset type
- Stock
- Market cap
- $77.5M
- Sector
- Health Technology
- Industry
- Pharmaceuticals: Major
- Exchange
- NYSE
- Currency
- USD
Annovis Bio, Inc. ANVS:NYSE stock context
This page tracks Annovis Bio, Inc.'s ANVS:NYSE listing on NYSE in USD for US, including stock price context, company news, filings, investor events, AI research briefs, and market updates for investors following ANVS:NYSE. ANVS:NYSE is the stock-level entry point for investors researching Annovis Bio, Inc., while company-level investor report content can remain shared across the same issuer's public listings. 6ix connects this selected listing to available company updates, filings, investor events, replay content, and AI research briefs so stock search leads to the relevant company context without making another exchange listing primary. Annovis Bio, Inc. (ticker: ANVS) is a public company based in America, with a market capitalization of approximately $70.6 million. The company focuses on developing therapies for neurodegenerative diseases. Annovis Bio aims to address significant unmet medical needs through its innovative research and development efforts.
Latest news from Annovis Bio, Inc.
Annovis to Host Corporate Update Webinar on September 2, 2026
August 25, 2026
Annovis Provides Corporate Updates and Second Quarter 2026 Financial Results
August 14, 2026
Annovis Reaches Full Enrollment in Pivotal Phase 3 Trial of Buntanetap for Early Alzheimer’s Disease
July 7, 2026
Annovis Bio Regains NYSE Listing Compliance
May 26, 2026
Annovis Announces Pricing of $15.0 Million Public Offering of Common Stock and Accompanying Warrants
May 20, 2026
Research Annovis Bio, Inc.
Annovis Bio, Inc. investor report
Review AI stock analysis and investor report context for ANVS:NYSE.
Annovis Bio, Inc. company profile
View the public company page for Annovis Bio, Inc. on 6ix.
Annovis Bio, Inc. news
Read company news and market updates connected to Annovis Bio, Inc..
Annovis Bio, Inc. investor events
Find investor webinars, events, and replay context for Annovis Bio, Inc..
Alternate listings
A2PNH2:LSX
DE · EUR
Alternate listing for Annovis Bio, Inc.; the primary context on this page is ANVS:NYSE.
07X:GETTEX
DE · EUR
Alternate listing for Annovis Bio, Inc.; the primary context on this page is ANVS:NYSE.
A2PNH2:LS
DE · EUR
Alternate listing for Annovis Bio, Inc.; the primary context on this page is ANVS:NYSE.
ANVS:BOATS
US · USD
Alternate listing for Annovis Bio, Inc.; the primary context on this page is ANVS:NYSE.
07X:DUS
DE · EUR
Alternate listing for Annovis Bio, Inc.; the primary context on this page is ANVS:NYSE.
07X:FWB
DE · EUR
Alternate listing for Annovis Bio, Inc.; the primary context on this page is ANVS:NYSE.
07X:MUN
DE · EUR
Alternate listing for Annovis Bio, Inc.; the primary context on this page is ANVS:NYSE.
07X:SWB
DE · EUR
Alternate listing for Annovis Bio, Inc.; the primary context on this page is ANVS:NYSE.
07X:TRADEGATE
DE · EUR
Alternate listing for Annovis Bio, Inc.; the primary context on this page is ANVS:NYSE.